1. Home
  2. TBPH vs CCO Comparison

TBPH vs CCO Comparison

Compare TBPH & CCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

N/A

Current Price

$19.26

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Logo Clear Channel Outdoor Holdings Inc.

CCO

Clear Channel Outdoor Holdings Inc.

N/A

Current Price

$2.39

Market Cap

1.2B

ML Signal

N/A

Company Overview

Basic Information
Metric
TBPH
CCO
Founded
2013
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Advertising
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2013
2005

Fundamental Metrics

Financial Performance
Metric
TBPH
CCO
Price
$19.26
$2.39
Analyst Decision
Strong Buy
Hold
Analyst Count
5
6
Target Price
$27.80
$2.10
AVG Volume (30 Days)
386.5K
8.3M
Earning Date
01-01-0001
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
110.81
EPS
0.88
0.04
Revenue
$15,386,000.00
$1,604,140,000.00
Revenue This Year
$70.90
$6.76
Revenue Next Year
N/A
$4.42
P/E Ratio
$21.66
$120.00
Revenue Growth
N/A
6.57
52 Week Low
$7.90
$0.81
52 Week High
$21.03
$2.43

Technical Indicators

Market Signals
Indicator
TBPH
CCO
Relative Strength Index (RSI) 45.07 63.48
Support Level $18.27 $1.96
Resistance Level $19.04 N/A
Average True Range (ATR) 0.91 0.04
MACD -0.09 0.00
Stochastic Oscillator 23.72 92.00

Price Performance

Historical Comparison
TBPH
CCO

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About CCO Clear Channel Outdoor Holdings Inc.

Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.

Share on Social Networks: